Avantogen- New Test Proves Effective in More Cancers

Avantogen Limited today announced that cancer researchers at Perth's Telethon Institute for Child Health Research (TICHR) and Avantogen Limited have achieved an important milestone towards more individually targeted and effective treatments for cancer patients.

The research team has now identified crucial genes in a range of common cancers that have been reported to predict a patient's response to treatment. This follows the team's earlier success in studying a tumor suppressor gene associated with acute lymphoblastic leukaemia (ALL) in children.

By using a simple test developed at the Institute, they can rapidly detect the presence or absence of these tumor suppressor genes in the patient's cancer cells. Tumor suppressor genes are linked to a variety of cancers including lung, breast, renal, colorectal, pancreatic, gastric, lymphoma and malignant melanoma.

Read more: Avantogen- New Test Proves Effective in More Cancers